{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:32:11Z","timestamp":1740130331073,"version":"3.37.3"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RAPID-axSpA","award":["NCT01087762"],"award-info":[{"award-number":["NCT01087762"]}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Olivia Wakeman and Jessica Patel, Costello Medical"},{"name":"UCB Pharma in accordance with Good Publication Practice","award":["GPP3"],"award-info":[{"award-number":["GPP3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Fat lesions (FLs) on MRI T1 sequences are considered to be early indicators of structural spinal progression in axial spondyloarthritis (axSpA) patients. In this post-hoc analysis from RAPID-axSpA, we assess whether tumour necrosis factor inhibitor (TNFi) treatment over 4\u2009years impacts FLs in spinal vertebral edges (VEs) of patients with axSpA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In RAPID-axSpA (NCT01087762), a 4-year, phase 3 randomized trial, participants were randomized to certolizumab pegol (CZP; 400\u2009mg loading dose at Weeks 0\/2\/4 then 200\/400\u2009mg every 2\/4\u2009weeks) or placebo (PBO) at baseline; PBO-randomized participants switched to CZP at Week 16\/24 (denoted PBO-randomized\/CZP). Spinal MRI scans were taken at Weeks 0, 12, 48, 96 and 204. Changes in proportions of VEs with FLs are reported as odds ratios (ORs) between time points.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 136 participants (CZP: 89, PBO-randomized\/CZP: 47) had a baseline and \u22651 post-baseline MRI. The OR (95% confidence interval) vs baseline of FLs was higher in PBO-randomized\/CZP vs CZP-randomized participants at Weeks 48 [3.35 (2.16\u20135.19) vs 1.45 (1.07\u20131.97)], 96 [2.62 (1.77\u20133.88) vs 1.84 (1.36\u20132.48)] and 204 [2.55 (1.59\u20134.06) vs 1.71 (1.23\u20132.37)]. Across 204\u2009weeks, FLs increased more in VEs with baseline inflammation [Week 204 OR: 4.84 (2.56\u20139.18)] than those without [OR: 1.15 (0.78\u20131.71)]. VEs in which inflammation was resolved by Week 12 had lower FL prevalence at Weeks 48, 96 and 204 compared with VEs with unresolved inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Early and sustained suppression of inflammation mitigates the risk of long-term FL development in the spine in study participants with axSpA evaluated over 4\u2009years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT01087762.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keab841","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T12:10:49Z","timestamp":1636632649000},"page":"2875-2885","source":"Crossref","is-referenced-by-count":4,"title":["Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum , Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Kruse","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum , Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone E","family":"Auteri","sequence":"additional","affiliation":[{"name":"UCB Pharma , Brussels, Belgium and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"de Peyrecave","sequence":"additional","affiliation":[{"name":"UCB Pharma , Brussels, Belgium and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommi\u00a0","family":"Nurminen","sequence":"additional","affiliation":[{"name":"UCB Pharma , Monheim am Rhein, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kumke","sequence":"additional","affiliation":[{"name":"UCB Pharma , Monheim am Rhein, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Hoepken","sequence":"additional","affiliation":[{"name":"UCB Pharma , Monheim am Rhein, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-5095","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Braun","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum , Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"2022070614093213600_keab841-B1","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"2022070614093213600_keab841-B2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3899\/jrheum.080871","article-title":"The natural course of radiographic progression in ankylosing spondylitis\u2014evidence for major individual variations in a large proportion of patients","volume":"36","author":"Baraliakos","year":"2009","journal-title":"J Rheumatol"},{"key":"2022070614093213600_keab841-B3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11926-017-0681-5","article-title":"Mechanism of new bone formation in axial spondyloarthritis","volume":"19","author":"Poddubnyy","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"2022070614093213600_keab841-B4","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3899\/jrheum.160003","article-title":"Serum C-reactive protein levels demonstrate predictive value for radiographic and magnetic resonance imaging outcomes in patients with active ankylosing spondylitis treated with golimumab","volume":"43","author":"Braun","year":"2016","journal-title":"J Rheumatol"},{"key":"2022070614093213600_keab841-B5","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/annrheumdis-2018-214983","article-title":"What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis","volume":"78","author":"Baraliakos","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022070614093213600_keab841-B6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/art.23260","article-title":"Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes","volume":"58","author":"Sieper","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"2022070614093213600_keab841-B7","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/art.30393","article-title":"Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis","volume":"63","author":"Chiowchanwisawakit","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"2022070614093213600_keab841-B8","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/annrheumdis-2013-203425","article-title":"Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022070614093213600_keab841-B9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/ar4561","article-title":"The window of opportunity: a relevant concept for axial spondyloarthritis","volume":"16","author":"Robinson","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2022070614093213600_keab841-B10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/annrheumdis-2011-200859","article-title":"Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification","volume":"72","author":"Maksymowych","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022070614093213600_keab841-B11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/ard.2010.147033","article-title":"Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022070614093213600_keab841-B12","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2022070614093213600_keab841-B13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022070614093213600_keab841-B14","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"2022070614093213600_keab841-B15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022070614093213600_keab841-B16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022070614093213600_keab841-B17","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"2022070614093213600_keab841-B18","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.38775","article-title":"Brief report: erosions and sclerosis on radiographs precede the subsequent development of syndesmophytes at the same site: a twelve-year prospective followup of patients with ankylosing spondylitis","volume":"66","author":"Ramiro","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022070614093213600_keab841-B19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomized placebo-controlled Phase 3 study","volume":"73","author":"Landewe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022070614093213600_keab841-B20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","article-title":"Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomized trial","volume":"77","author":"van der Heijde","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022070614093213600_keab841-B21","doi-asserted-by":"crossref","first-page":"e000430","DOI":"10.1136\/rmdopen-2017-000430","article-title":"Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis","volume":"3","author":"Braun","year":"2017","journal-title":"RMD Open"},{"key":"2022070614093213600_keab841-B22","first-page":"ii1","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68 Suppl 2","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022070614093213600_keab841-B23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika"},{"volume-title":"SAS\/STAT\u00ae 13.1 User\u2019s Guide","year":"2013","key":"2022070614093213600_keab841-B24"},{"key":"2022070614093213600_keab841-B25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40744-020-00214-7","article-title":"Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment: 48-week outcomes from C-OPTIMISE","volume":"7","author":"Landew\u00e9","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2022070614093213600_keab841-B26","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A fifty-two\u2013week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022070614093213600_keab841-B27","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1136\/annrheumdis-2015-208011","article-title":"MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis","volume":"75","author":"Machado","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022070614093213600_keab841-B28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.semarthrit.2015.08.005","article-title":"Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis\u20143-year data of the ESTHER trial","volume":"45","author":"Song","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2022070614093213600_keab841-B29","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","article-title":"The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial","volume":"73","author":"Braun","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab841\/42559619\/keab841.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/7\/2875\/44473576\/keab841.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/7\/2875\/44473576\/keab841.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T14:03:21Z","timestamp":1699797801000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/7\/2875\/6428679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,11,15]]},"published-print":{"date-parts":[[2022,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab841","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,11,15]]}}}